Bronchiectasis: New approaches to diagnosis and management

Clinics in Chest Medicine

Volumn 32, Issue 3, 2011, Pages 535-546

  Feldman, Charles ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Bronchiectasis; Corticosteroids; High resolution ct scan; Macrolides; Physiotherapy; Vaccination

Indexed keywords

AZITHROMYCIN; BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLARITHROMYCIN; CORTICOSTEROID; ERDOSTEINE; ERYTHROMYCIN; FLUTICASONE PROPIONATE; INFLUENZA VACCINE; MACROLIDE; METHYLXANTHINE DERIVATIVE; MUCOLYTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OXYGEN; PLACEBO; PNEUMOCOCCUS VACCINE; ROXITHROMYCIN; TIOTROPIUM BROMIDE;

BACTERIUM CULTURE; BREATHING EXERCISE; BRONCHIECTASIS; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DIAGNOSTIC PROCEDURE; DISEASE EXACERBATION; DYSPNEA; EXERCISE; FATIGUE; GASTROINTESTINAL DISEASE; HAEMOPHILUS INFLUENZAE; HEART DISEASE; HEMOPTYSIS; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INFLUENZA; LEICESTER COUGH QUESTIONNAIRE; LETHARGY; LUNG FUNCTION TEST; LUNG SURGERY; MALAISE; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; MEDICAL RESEARCH; MORAXELLA CATARRHALIS; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITIONAL SUPPORT; OXYGEN THERAPY; PATIENT CARE; PNEUMOCOCCAL INFECTION; POSITIVE END EXPIRATORY PRESSURE; POSTURAL DRAINAGE; PRIORITY JOURNAL; PROGNOSIS; PSEUDOMONAS AERUGINOSA; PULMONARY REHABILITATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SMOKING CESSATION; SPUTUM ANALYSIS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; THORAX PAIN; THORAX RADIOGRAPHY; WEIGHT REDUCTION;

ADRENAL CORTEX HORMONES; ANTI-BACTERIAL AGENTS; BRONCHIECTASIS; BRONCHODILATOR AGENTS; EXPECTORANTS; HUMANS; MACROLIDES; RESPIRATORY THERAPY;

EID: 80051907331     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2011.05.002     Document Type: Review

References (101)

1. Pappalettera M., Aliberti S., Castellotti P., et al. Bronchiectasis: an update. Clin Respir J 2009, 3:1752-6981.
2. Stafler P., Carr S.B. Non-cystic fibrosis bronchiectasis: its diagnosis and management. Arch Dis Child Educ Pract Ed 2010, 95:73-82.
3. Leikin J.B. Bronchiectasis. Dis Mon 2008, 54:514-564.
4. Pasteur M.C., Bilton D., Hill A.T., et al. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010, 65:i1-i58.
5. Roberts H.J., Hubbard R. Trends in bronchiectasis mortality in England and Wales. Respir Med 2010, 104:981-985.
6. Al Subie H., Fitzgerald D.A. Non-cystic fibrosis bronchiectasis. J Paediatr Child Health 2010, 10.1111/j.1365-2230.2010.03857.x.
7. Goeminne P., Dupont L. Non-cystic fibrosis bronchiectasis: diagnosis and management in 21st century. Postgrad Med J 2010, 86:493-501.
8. Seitz A.E., Olivier K.N., Steiner C.A., et al. Trends and burden of bronchiectasis-associated hospitalizations in the United States, 1993-2006. Chest 2010, 138(4):944-949.
9. Weycker D., Edelsberg J., Oster G., et al. Prevalence and economic burden of bronchiectasis. Clin Pulm Med 2005, 12:205-209.
10. King P.T., Daviskas E. Pathogenesis and diagnosis of bronchiectasis. Breathe 2010, 6:343-351.
11. Dagli E. Non cystic fibrosis bronchiectasis. Paediatr Respir Rev 2000, 1:64-70.
12. Fuschilllo S., De Felice A., Balzano G. Mucosal inflammation in idiopathic bronchiectasis: cellular and molecular mechanisms. Eur Respir J 2008, 31:396-406.
13. King P.T. The pathophysiology of bronchiectasis. Int J Chron Obstruct Pulmon Dis 2009, 4:411-419.
14. Javidan-Nejad C., Bhalla S. Bronchiectasis. Radiol Clin North Am 2009, 47:289-306.
15. Tsang K.W., Bilton D. Clinical challenges in managing bronchiectasis. Respirology 2009, 14:637-650.
16. Cole P.J. Inflammation: a two-edged sword-the model of bronchiectasis. Eur J Respir Dis Suppl 1986, 147:6-15.
17. Li A.M., Sonnappa S., Lex C., et al. Non-CF bronchiectasis: does knowing the aetiology lead to changes in management?. Eur Respir J 2005, 26:8-14.
18. Shoemark A., Ozerovitch L., Wilson R. Aetiology in adult patients with bronchiectasis. Respir Med 2007, 101:1163-1170.
19. Rosen M.J. Chronic cough due to bronchiectasis. Chest 2006, 129(Suppl):122S-131S.
20. Zoumot Z., Wilson R. Respiratory infection in noncystic fibrosis bronchiectasis. Curr Opin Infect Dis 2010, 23:165-170.
21. Loebinger M.R., Wilson R. Pharmacotherapy for bronchiectasis. Expert Opin Pharmacother 2007, 8(18):3183-3193.
22. O'Donnell A.E. Bronchiectasis. Chest 2008, 134:815-823.
23. Martinez-Garcia M.A., Perpina-Tordera M., Roman-Sanchez P., et al. Quality-of-life determinants in patients with clinically stable bronchiectasis. Chest 2005, 128:739-745.
24. Murray M.P., Turnbull K., MacQuarrie S., et al. Validation of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis. Eur Respir J 2009, 34(1):125-131.
25. Wilson R. Bronchiectasis. Respiratory infections 2001, 47-359. Lippincott, Williams and Wilkins, Philadelphia. 2nd edition. M.S. Niederman, G. Sarosi, J. Glassroth (Eds.).
26. Sheehan R.E., Wells A.U., Copley S.J., et al. A comparison of serial computed tomography and functional change in bronchiectasis. Eur Respir J 2002, 20:581-587.
27. Eshed I., Minski I., Katz R., et al. Bronchiectasis: correlation of high resolution CT findings with health-related quality of life. Clin Radiol 2007, 62:152-159.
28. Alzeer A.H. HRCT score in bronchiectasis: correlation with pulmonary function tests and pulmonary artery pressure. Ann Thorac Med 2008, 3:82-86.
29. Montella S., Santamaria F., Salvatore M., et al. Assessment of chest high-field magnetic resonance imaging in children and young adults with noncystic fibrosis chronic lung disease: comparison to high-resolution computed tomography and correlation with pulmonary function. Invest Radiol 2009, 44:532-538.
30. Ilowite J., Spiegler P., Kessler H. Pharmacological treatment options for bronchiectasis. Focus on antimicrobial and anti-inflammatory agents. Drugs 2009, 69(4):407-419.
31. Ten Hacken N., Kerstjens H., Postma D. Bronchiectasis. Clin Evid (Online) 2008, 2008:1507.
32. King P.T., Daviskas E. Management of bronchiectasis. Breathe 2010, 6:353-364.
33. Sharples L.D., Edmunds J., Bilton D., et al. A randomized controlled crossover trial of nurse practitioner versus doctor led outpatient care in a bronchiectasis clinic. Thorax 2002, 57:661-666.
34. French J., Bilton D., Campbell F. Nurse specialist care for bronchiectasis. Cochrane Database Syst Rev 2003, 3. CD004319.
35. Chang C.C., Morris P.S., Chang A.B. Influenza vaccine for children and adults with bronchiectasis. Cochrane Database Syst Rev 2007, 3. CD006218.
36. Chang C.C., Singleton R.J., Morris P.S., et al. Pneumococcal vaccine for children and adults with bronchiectasis. Cochrane Database Syst Rev 2009, 2. CD006316.
37. Murray M.P., Pentland J.L., Hill A.T. A randomized crossover trial of chest physiotherapy in non-cystic fibrosis bronchiectasis. Eur Respir J 2009, 34:1086-1092.
38. Martinez-Garcia M.A., Soriano J.B. Physiotherapy in bronchiectasis: we have more patients, we need more evidence. Eur Respir J 2009, 34:1011-1012.
39. Eaton T., Young P., Zeng I., et al. A randomized evaluation of the acute efficacy, acceptability and tolerability of flutter and active cycle of breathing with and without postural drainage in non-cystic fibrosis bronchiectasis. Chron Respir Dis 2007, 4:23-30.
40. Bradley J., Moran F., Greenstone M. Physical training for bronchiectasis. Cochrane Database Syst Rev 2002, 3. CD002166.
41. Crockett A.J., Cranston J.M., Latimer K.M., et al. Mucolytics for bronchiectasis. Cochrane Database Syst Rev 2000, 2. CD001289.
42. Metersky M.L. New treatment options for bronchiectasis. Ther Adv Respir Dis 2010, 4:93-99.
43. Chang A.B., Bilton D. Exacerbations in cystic fibrosis: 4-Non-cystic fibrosis bronchiectasis. Thorax 2008, 63:269-276.
44. Daviskas E., Anderson S.D., Eberl S., et al. Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis. Am J Respir Crit Care Med 1999, 159(6):1843-1848.
45. Daviskas E., Anderson S.D., Eberl S., et al. The 24-h effect of mannitol on the clearance of mucus in patients with bronchiectasis. Chest 2001, 119:414-421.
46. Daviskas E., Anderson S.D., Gomes K., et al. Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: effect on lung function, health status and sputum. Respirology 2005, 10(1):46-56.
47. Daviskas E., Anderson S.D., Eberl S., et al. Effect of increasing doses of mannitol on mucus clearance in patients with bronchiectasis. Eur Respir J 2008, 31:765-772.
48. Daviskas E., Anderson S.D., Young I.H. Effect of mannitol and repetitive coughing on the sputum properties in bronchiectasis. Respir Med 2010, 104:371-377.
49. Wills P., Greenstone M. Inhaled hyperosmolar agents for bronchiectasis. Cochrane Database Syst Rev 2006, 2. CD002996.
50. Kellett F., Redfern J., Niven R.M. Evaluation of nebulised hypertonic saline (7%) as an adjunct to physiotherapy in patients with stable bronchiectasis. Respir Med 2005, 99(1):27-31.
51. Hassan J.A., Saadiah S., Roslan H., et al. Bronchodilator response to inhaled beta-2 agonist and anticholinergic drugs in patients with bronchiectasis. Respirology 1999, 4:423-426.
52. Sheikh A., Nolan D., Greenstone M. Long-acting beta-2-agonists for bronchiectasis. Cochrane Database Syst Rev 2001, 4. CD002155.
53. Lasserson T., Holt K., Evans D., et al. Anticholinergic therapy for bronchiectasis. Cochrane Database Syst Rev 2001, 4. CD002163.
54. Steele K., Greenstone M., Lasserson J.A. Oral methyl-xanthines for bronchiectasis. Cochrane Database Syst Rev 2001, 1. CD002734.
55. Franco F., Sheikh A., Greenstone M. Short acting beta-2 agonists for bronchiectasis. Cochrane Database Syst Rev 2003, 3. CD003572.
56. Saito Y., Azuma A., Morimoto T., et al. Tiotropium ameliorates symptoms in patients with chronic airway mucus hypersecretion which is resistant to macrolide therapy. Intern Med 2008, 47:585-591.
57. Corless J.A., Warburton C.J. Leukotriene receptor antagonists for non-cystic fibrosis. Cochrane Database Syst Rev 2000, 4. CD002174.
58. Murray M.P., Turnbull K., MacQuarrie S., et al. Assessing response to treatment of exacerbations of bronchiectasis in adults. Eur Respir J 2009, 33:312-317.
59. Hill S.L., Burnett D., Hewetson K.A., et al. The response of patients with purulent bronchiectasis to antibiotics for four months. Q J Med 1988, 66(250):163-173.
60. Currie D.C., Garbett N.D., Chan K.L., et al. Double-blind randomized study of prolonged higher-dose oral amoxicillin in purulent bronchiectasis. Q J Med 1990, 76(280):799-816.
61. Rayner C.F., Tillotson G., Cole P.J., et al. Efficacy and safety of long-term ciprofloxacin in the management of severe bronchiectasis. J Antimicrob Chemother 1994, 34(1):149-156.
62. Evans D.J., Greenstone M. Long-term antibiotics in the management of non-CF bronchiectasis-do they improve outcome?. Respir Med 2003, 97:851-858.
63. Evans D.J., Bara A., Greenstone M. Prolonged antibiotics for purulent bronchiectasis in children and adults. Cochrane Database Syst Rev 2007, 2. CD001392.
64. Drobnic M.E., Sune P., Montoro J.B., et al. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother 2005, 39(1):39-44.
65. Scheinberg P., Shore E. A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest 2005, 127:1420-1426. on behalf of the PC-TNDS-008 Study Group.
66. Bilton D., Henig N., Morrissey B., et al. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest 2006, 130:1503-1510.
67. Murray M.P., Govan J.R., Doherty C.J., et al. A randomized controlled trial of nebulised gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2011, 183(4):491-499.
68. Orriols R., Rolg J., Ferrer J., et al. Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa. Respir Med 1999, 93(7):476-480.
69. Macleod D.L., Barker L.M., Sutherland J.L., et al. Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis. J Antimicrob Chemother 2009, 64(4):829-836.
70. Rubin B.K. Aerosolized antibiotics for non-cystic fibrosis bronchiectasis. J Aerosol Med Pulm Drug Deliv 2008, 21(1):71-76.
71. Tsang K.W., Tan K.C., Ho P.L., et al. Inhaled fluticasone in bronchiectasis: a 12 month study. Thorax 2005, 60(3):239-243.
72. Martinez-Garcia M.A., Perpina-Tordera M., Roman-Sanchez P., et al. Inhaled steroids improve quality of life in patients with steady-state bronchiectasis. Respir Med 2006, 100:1623-1632.
73. Kapur N., Bell S., Kolbe J., et al. Inhaled steroids for bronchiectasis. Cochrane Database Syst Rev 2009, 1. CD000996.
74. King P. Is there a role for inhaled corticosteroids and macrolide therapy in bronchiectasis?. Drugs 2007, 67:965-974.
75. Elborn J.S., Johnston B., allen F., et al. Inhaled steroids in patients with bronchiectasis. Respir Med 1992, 86:121-124.
76. Tsang K.W., Ho P.L., Lam W.K., et al. Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis. Am J Respir Crit Care Med 1998, 158:723-727.
77. Holme J., Tomlinson J.W., Stockley R.A., et al. Adrenal suppression in bronchiectasis and the impact of inhaled corticosteroids. Eur Respir J 2008, 32:1047-1052.
78. Lasserson T., Holt K., Greenstone M. Oral steroids for bronchiectasis (stable and acute exacerbations). Cochrane Database Syst Rev 2001, 4. CD002162.
79. Pizzutto S.J., Upham J.W., Yerkovich S.T., et al. Inhaled non-steroid anti-inflammatories for children and adults with bronchiectasis (review). Cochrane Database Syst Rev 2010, 4. CD007525.
80. Kapur N., Chang A.B. Oral non steroid anti-inflammatories for children and adults with bronchiectasis. Cochrane Database Syst Rev 2007, 4. CD006427.
81. Tsang K.W., Ho P.I., Chan K.N., et al. A pilot study of low-dose erythromycin in bronchiectasis. Eur Respir J 1999, 13:361-364.
82. Tagaya E., Tamaoki J., Kondo M., et al. Effect of a short course of clarithromycin therapy on sputum production in patients with chronic airway hypersecretion. Chest 2002, 122(1):213-218.
83. Cymbala A.A., Edmonds L.C., Bauer M.A., et al. The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis. Treat Respir Med 2005, 4(2):117-122.
84. Yalcin E., Kiper N., Ozcelik U., et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. J Clin Pharm Ther 2006, 31:49-55.
85. Anwar G.A., Bourke S.C., Afolabi G., et al. Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis. Respir Med 2008, 102:1494-1496.
86. Crosbie P.A.J., Woodhead M.A. Long-term macrolide therapy in chronic inflammatory airway disease. Eur Respir J 2009, 33:171-181.
87. Friedlander A.L., Albert R.K. Chronic macrolide therapy in inflammatory airways diseases. Chest 2010, 138(5):1202-1212.
88. Koh Y.Y., Lee M.H., Sun Y.H., et al. Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study. Eur Respir J 1997, 10:994-999.
89. Davies G., Wilson R. Prophylactic antibiotic treatment of bronchiectasis with azithromycin. Thorax 2004, 59:540-541.
90. Altenburg J., de Graaff C.S., van der Werf T.S., et al. Immunomodulatory effects of macrolide antibiotics-part 2: advantages and disadvantages of long-term, low-dose macrolide therapy. Respiration 2011, 81(1):75-87.
91. Giamarellos-Bourboulis E.J. Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators. Int J Antimicrob Agents 2008, 31:12-20.
92. Fujimoto T., Hillejan L., Stamatis G. Current strategy for surgical management of bronchiectasis. Ann Thorac Surg 2001, 72:1711-1715.
93. Balkanli K., Genc O., Dakak M., et al. Surgical management of bronchiectasis: analysis and short-term results in 238 patients. Eur J Cardiothorac Surg 2003, 24:699-702.
94. Giovannetti R., Alifano M., Stefani A., et al. Surgical treatment of bronchiectasis: early and long-term results. Interact Cardiovasc Thorac Surg 2008, 7:609-612.
95. Titman A., Rogers C.A., Bonser R.S., et al. Disease-specific survival benefit of lung transplantation in adults: a national cohort study. Am J Transplant 2009, 9:1640-1649.
96. Bagheri R., Haghi S.Z., Fattahi Masoum S.H., et al. Surgical management of bronchiectasis: analysis of 277 patients. Thorac Cardiovasc Surg 2010, 58(5):291-294.
97. Gursoy S., Ozturk A.A., Ucvet A., et al. Surgical management of bronchiectasis: the indications and outcomes. Surg Today 2010, 40:26-30.
98. Hayes D., Meyer K.C. Lung transplantation for advanced bronchiectasis. Semin Respir Crit Care Med 2010, 31(2):123-138.
99. Zhang P., Jiang G., Ding J., et al. Surgical treatment of bronchiectasis: a retrospective analysis of 790 patients. Ann Thorac Surg 2010, 90:246-251.
100. Corless J.A., Warburton C.J. Surgery vs non-surgical treatment for bronchiectasis. Cochrane Database Syst Rev 2000, 4. CD002180.
101. Prasad M., Tino G. Bronchiectasis, part 2: management. J Respir Dis 2008, 29(1):20-25.